Concurrent Investment Advisors LLC Has $591,000 Position in Sanofi $SNY

Concurrent Investment Advisors LLC increased its stake in shares of Sanofi (NASDAQ:SNY) by 26.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 12,226 shares of the company’s stock after buying an additional 2,526 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Sanofi were worth $591,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Perigon Wealth Management LLC lifted its stake in Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company’s stock valued at $367,000 after acquiring an additional 201 shares during the last quarter. Capital Analysts LLC lifted its stake in Sanofi by 14.0% in the first quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock valued at $92,000 after acquiring an additional 204 shares during the last quarter. Thomasville National Bank lifted its stake in Sanofi by 0.3% in the second quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock valued at $3,886,000 after acquiring an additional 211 shares during the last quarter. Hexagon Capital Partners LLC lifted its stake in Sanofi by 4.2% in the first quarter. Hexagon Capital Partners LLC now owns 5,959 shares of the company’s stock valued at $330,000 after acquiring an additional 238 shares during the last quarter. Finally, U.S. Capital Wealth Advisors LLC lifted its stake in Sanofi by 4.1% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 6,227 shares of the company’s stock valued at $301,000 after acquiring an additional 247 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of analyst reports. Barclays reiterated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $62.67.

Sanofi Price Performance

Shares of Sanofi stock opened at $50.62 on Friday. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The firm has a fifty day simple moving average of $48.49 and a 200-day simple moving average of $49.63. The stock has a market capitalization of $124.30 billion, a price-to-earnings ratio of 12.17, a PEG ratio of 1.22 and a beta of 0.51. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same period last year, the firm posted $1.73 EPS. The company’s revenue was down 7.0% compared to the same quarter last year. On average, sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.